Corona | Sciomics is fully operational

Dear partners and friends,
We from Sciomics are hoping that you are all safe and well and would like to give you an update on our current activities in these challenging times.

To limit the spread of the COVID-19 virus and to ensure the safety of our employees as well as the continuation of all projects, Sciomics has early implemented preventive actions which have recently been further increased:

- only people critical to the laboratory activity are present on site
- implementation of non-overlapping teams for all on-site activities
- efficient home office capabilities for all personnel

Through these actions, all our protein and post-translational analysis capabilities remain fully operational and we are able to continue all active projects as well as to begin new studies in the foreseeable future.
Please feel free to contact us at any time if you have any questions or like to discuss how we may support you best during the current situation as well as in future projects.

As health is the highest good, we wish you all the best for you as well as your families and loved ones.

covid 19 operational v3 web

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1,300 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels…

Read more

scioDiscover - Protein Profiling on expression level

scioDiscover - Protein Profiling on expression level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…

scioCD - Cell surface marker and Cytokine profiling

scioCD - Cell surface marker and Cytokine profiling

Characterise a certain cell type? Cell composition in a certain tissue sample? In-depth profiling of CD-marker expression? Increase your throughput at high sensitivity levels? You aim…

scioUbi

scioUbi

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay. Features Screen…

scioCyto : Cytokine profiling

scioCyto : Cytokine profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or…

New article | Biomarkers for canine mammary neoplasia

| Mai 2023 | New Article: Galadima et al. used the scioCD assay to analyse canine blood samples in the context of mammary neoplasia. The proteins CD20, CD45RA and CD99 were found at altered levels. The findings were validated by Western Blotting and are suggested as novel serum biomarkers.

Galadima et al. Canine Mammary Neoplasia Induces Variations in the Peripheral Blood Levels of CD20, CD45RA, and CD99 (2023) Int. J. Mol. Sci. 24(11)

New article | Microbiota influences chemotherapy in pancreatic cancer

| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.

Tintelnot et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168-174 (2023)

New article | HAPLN1 potentiates peritoneal metastasis in pancreatic cancer

| April 2023 | New Article: Wiedmann et al. identified HAPLN1 as a prognostic marker and as a and as a driver for peritoneal metastasis in pancreatic cancer. Sciomics contributed a plasma protein profiling of a mouse model to support this exciting study.

Wiedmann L et al. HAPLN1 potentiates peritoneal metastasis in pancreatic cancer. Nature Communications 14,2354 (2023)

New article | Predicting a severe Covid-19 disease

| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19 disease.

Hufnagel K., Fathi A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Communications Medicine 3,51 (2023)

New article | Prevention of Cyclosp.-A mediated anemia and peritubular loss

| June 2022 | In a study by Robert Labes et al. insights in prevention of cyclosporine mediated anemia and peritubular capillary loss were identified.

Labes, R. et al. Daprodust. prevents cyclosp.-A mediated anemia and peritubular capillary loss. Kidney International 2022 in press.

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD

Kyriaki Barmpa

PhD Candidate, Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine, University of Luxembourg

"By collaborating with Sciomics, we conducted a detailed analysis of the proteome of striatum organoids, uncovering significant differences that further assisted our research. Their communication was highly efficient, and the results were delivered promptly."

Product: scioPhospho

over a year ago